A critical advance in cancer research is arising with the use of mini-antibodies to re-engage dysfunctional p53. This essential malignant suppressor protein is frequently disabled in various kinds of cancer, resulting https://socials360.com/story12630049/mini-antibodies-reactivate-tumor-suppressor-p53-the-new-hope-for-malignant-therapy